Effect of Saliva Substitutes on Dental Hard Tissues in Situ

NCT ID: NCT01165970

Last Updated: 2011-11-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Symptomatic hyposalivation is associated not only with Sjögren's syndrome or salivary gland hypofunction in elderly patients, but also with medications containing antimuscarinic drugs, chemo radiotherapy for head and neck carcinomas, and psychiatric disorders (Atkinson \& Ava, 1994, Kielbassa et al., 2006).

Human saliva possesses important physiological functions in protecting and moistening the oral hard and soft tissues (Piotrowski et al., 1992, ). Consequently, decreasing salivation causes oral dysfunction and promotes severe oral side effects (reduced antibacterial function, lack of remineralisation, reduced buffer capacity) (Tschoppe et al., 2010a). These have been identified as being responsible for the rapid destruction of the dentition (Willich et al., 1988). Saliva substitutes are frequently applied for relieving the symptoms in patients suffering from hyposalivation (Hahnel et al., 2009, Nieuw Amerongen \& Veerman, 2003, Vissink et al., 2004). Besides the moistening and lubrication of the oral mucosa, these products should also protect dental hard tissues. However, in vitro studies revealed that some marketed products have only a neutral or even a demineralising potential on enamel as well as on dentin (Kielbassa et al., 2001, Meyer-Lueckel et al., 2002, Smith et al., 2001, Tschoppe et al., 2009). Inorganic ions such as calcium, phosphates, and fluorides have been added to saliva substitutes in order to enhance their remineralising property or minimize their demineralising potential (Tschoppe et al., 2009). Furthermore, as most patients suffering from hyposalivation are elderly people, recessions and subsequently exposed dentin surfaces are very common. Since dentin is not as acid resistant as enamel, an earlier and more severe demineralisation can be expected (Saunders \& Meyerowitz, 2005).

Therefore, the current in situ study was performed to assess the effects of a demineralising and a remineralising saliva substitutes on the mineralisation of dental hard tissues. It was hypothesized that storage in Glandosane(cell pharm, Hannover, Germany) would not result in pronounced mineral loss of dentin specimens, and that storage in Saliva natura would not result in enhanced remineralisation when combined with a remineralising artificial saliva (Saliva natura supersaturated with respect to relevant calcium phosphates; medac, Hamburg, Germany) (H0). These null hypotheses were tested against the alternative hypothesis of a difference.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

see application for the German Federal Institute for Drugs and Medical Devices at Eudra-CT

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyposalivation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glandosane

After in situ exposition the enamel and dentin samples will demineralize with Glandosane.

Group Type ACTIVE_COMPARATOR

Glandosane

Intervention Type DRUG

according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product

Saliva natura

After in situ exposition the enamel and dentin samples will remineralize with Saliva natura

Group Type EXPERIMENTAL

Saliva natura

Intervention Type DEVICE

Saliva substitute without restriction to be used

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glandosane

according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product

Intervention Type DRUG

Saliva natura

Saliva substitute without restriction to be used

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glandosane, Cell Pharm, Germany Saliva natura, Medac, Germany

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* stimulated salivary flow rate \< 0.5 ml/min
* partial denture upper or lower jaw
* radiationtherapy in the head and neck area
* patient age above 18 years
* Signed informed consent (AMG §40 (1) 3b)

Exclusion Criteria

* stimulated salivary flow rate \> 0.5 ml/min
* missing partial denture upper or lower jaw
* missing Radiationtherapy in the head and neck area
* paraben allergy
* not signed informed consent (AMG §40 (1) 3b)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Charite University, Berlin, Germany

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Peter Tschoppe

Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Tschoppe, Dr

Role: PRINCIPAL_INVESTIGATOR

Department of Operative Dentistry and Periodontology, School of Dental Medicine, CharitéCentrum 3, Charité - Universitätsmedizin Berlin

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charite, Berlin, Germany

Berlin, State of Berlin, Germany

Site Status

Charité - Universitätsmedizin Berlin

Berlin, State of Berlin, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Tschoppe P, Wolf O, Eichhorn M, Martus P, Kielbassa AM. Design of a randomized controlled double-blind crossover clinical trial to assess the effects of saliva substitutes on bovine enamel and dentin in situ. BMC Oral Health. 2011 Apr 9;11:13. doi: 10.1186/1472-6831-11-13.

Reference Type DERIVED
PMID: 21477333 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://kons-paro.charite.de

please check the science subsite

http://www.ncbi.nlm.nih.gov/pubmed/20305867

Short review on the main problems in this patient population: Etiologic factors of hyposalivation and consequences for oral health. Quintessence Int. 2010 Apr;41(4):321-33. Review.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-005451-23

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

T-01/2008-005451-23

Identifier Type: -

Identifier Source: org_study_id